Robert Davis - San Diego CA, US Kimberly Vanover - San Diego CA, US Mario Rodriguez - Lihue HI, US
International Classification:
A61K031/538 A61K031/454
US Classification:
514230500, 514321000
Abstract:
Disclosed herein are compounds and methods for treating chronic neuropathic pain. It has been discovered that compounds that selectively interact with a muscarinic receptor subtype are effective in treating neuropathic pain. Specifically, compounds that selectively interact with the M1 muscarinic receptor subtype may be used.
- New York NY, US Robert E DAVIS - San Diego CA, US Kimberly Vanover - New York NY, US
International Classification:
C07D 519/00
Abstract:
The invention relates to a particular substituted heterocycle fused gamma-carboline, the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine Dreceptor signaling, sodium channel activity, and/or norepinephrine transporter activity.
The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.
- New York NY, US Robert DAVIS - San Diego CA, US Kimberly VANOVER - New York NY, US
International Classification:
A61K 31/4985 A61P 25/18 A61K 9/20 A61K 9/48
Abstract:
The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.
Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.
Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.
The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.
As per Kimberly Vanover, PhD, of Intra-Cellular Technologies in New York City, which is developing the medication, the drug, a serotonin 5-HT2A receptor antagonist named ITI-007, was having a side effect profile, which was not much different from placebo in a phase II trial.